NEIL CAVUTO: In some 1438 individuals in the New York area across 25 hospitals from the middle of March to the end of March. The study was a real chance to look at the benefits that the President insisted were the hydroxychloroquine. They concluded that among residents hospitalized in metropolitan New York with COVID-19, the treatment or both compared with neither treatment, no statistical differences. A second study done by Joshua Geleris and colleagues of the New York-Presbyterian Hospital, Colombia University Irving Medical Center in Northern Manhattan, from March 7th to April 8th, also showed there were no visible differences. That the risk of intubation or death was not significant only higher or lower among patients who received hydroxychloroquine versus those who did not.
The VA study to which the President alluded wasn't a loaded political one, it was a test on patients there. And those who took it in a vulnerable population including those with respiratory or other conditions, they died, I want to stress again they died. If you are in a risky population and you are taking this as a preventative treatment to ward off the virus or in a worst-case scenario, you are dealing with the virus, and you are in this vulnerable population, it will kill you. I cannot stress that enough. This will kill you.
So again, whatever benefit the President says this has, and it certainly has had for those that suffer from malaria, dealing with lupus, this is a leap that should not be taken casually by those watching at home who are assuming, well the president of the United States says it's okay. Even the FDA was very cautious about this. Unless in a clinical trial safely and deliberately watched. I only make this not to make a political point here, but a life and death point, be very, very careful.